3rd Millennium, Inc Company Profile

21:16 EDT 18th March 2018 | BioPortfolio

3rd Millennium, Inc. is the leading provider of custom informatics systems, management consulting services, and packaged software products for the life sciences.
Since 1994, we have helped both public and private life science institutions manage, plan, specify, design, build, and integrate informatics systems to support their research and development programs.

We provide our clients with outstanding value by combining our deep knowledge of life science R&D, cutting edge informatics technologies, a highly efficient methodology, and an extensive portfolio of designs, code libraries, frameworks, and implemented systems.

Our staff consists of Ph.D. level scientists and senior software engineers that work closely with our clients in tightly integrated teams. We have an unmatched record of completing projects on-time and on-budget while exceeding user expectations.


391 Totten Pond Road, Suite 104
United States of America


Phone: 781-890-4440

News Articles [32 Associated News Articles listed on BioPortfolio]

Andrew Lukowiak Departs AltheaDx to Become Millennium Health’s CEO

Andrew Lukowiak has been appointed CEO of Millennium Health. Lukowiak comes to San Diego-based Millennium from precision medicine company AltheaDx, also based in San Diego, where he was chief operatin...

QIAGEN-Aktie: Leerverkäufer Millennium International Management tritt den Rückzug an!

KJ Venlo - Leerverkäufer Millennium International Management LP kürzt Netto-Leerverkaufsposition in Aktien der QIAGEN N.V.: Die Hedgefonds-Manager von Millennium International Management LP treten ....

Millennium:Looking for First in Class and Best in Class Opportunities in Oncology and Hematology

In this episode of PharmaTelevision News Review, filmed at #BIO2012 Convention in Boston, Fintan Walton talks to Dan Curran, Vice President, Corporate Development at Millennium

Elle UK Interviews Daisy Ridley While She Builds A Lego Millennium Falcon

She’s talented and beautiful and she plays Luke Skywalker’s new padawan, Rey, in one of the most anticipated “Star Wars” films of all time, but now comes the true test: Can Daisy Ridley buil...

Twenty percent of millennium generation is obese, study finds

Twenty percent of young people born in the UK at the turn of the century were obese by the age of 14, while a further 15 percent were found to be overweight, according to data from UCL’s Millenn...

Millennium Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 19022018] Prices from USD $350

Millennium Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Millennium Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Al...

Sareum and Structure: An Interview with Tim Mitchell, CEO

Fintan Walton talks to Tim Mitchell, CEO, Sareum, about founding the company with David Williams and John Reader, as a spin-out from Millennium Pharmaceuticals' Structure-based Discovery Department. T...

Inflammatory arthritis disease activity improved in new millennium

Patients with early inflammatory polyarthritis diagnosed within the new millennium experienced improved disease activity, compared with those diagnosed during the early 1990s, according to findings pu...

Drugs and Medications [0 Results]


PubMed Articles [34 Associated PubMed Articles listed on BioPortfolio]

Syphilis Resurgence in Belgrade, Serbia, in the New Millennium: an Outbreak in 2014.

Transition from Millennium Development Goals to Sustainable Development Goals from the perspective of the social determinants of health and health equity.

The United Nations Declaration of 2000 agreed on eight millennium development goals (MDGs) to be met in 2015. The results show that poverty continues through population growth and advances in both ric...

Erratum: Local environmental quality positively predicts breastfeeding in the UK's Millennium Cohort Study.

[This corrects the article DOI: 10.1093/emph/eox011.][This corrects the article DOI: 10.1093/emph/eox011.].

Time trend of reported cases and publications: hepatitis E in comparison to hepatitis A - D in Germany from 2001 to 2016.

 The frequency of autochthonous hepatitis E virus (HEV) infections in Western countries has increased since the millennium, probably due to a higher awareness for HEV. The aim of this study was to a...

Long-Term Survivorship in Multiple Endocrine Neoplasia Type 2B diagnosed before and in the new Millennium.

Recent long-term outcome and survival data are lacking for patients with multiple endocrine neoplasia type 2B (MEN2B).

Clinical Trials [11 Associated Clinical Trials listed on BioPortfolio]

The Millennium Villages Project: Assessing the Impact on Child Survival and the Millennium Development Goals in Sub-Saharan Africa

The Millennium Villages Project involves the coordinated and simultaneous delivery of a package of proven interventions in health, agriculture, infrastructure and education. The project wo...

Treating Sleep Problems in VA Adult Day Health Care

The Veterans Millennium Health Care and Benefits Act (Millennium Act) of 1999 mandated the Department of Veterans Affairs (VA) to provide non-institutional long-term care to veterans. Adul...

MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age

This research study is evaluating drugs called Millennium 9708 (referred to as MLN9708) in combination with standard therapy for acute myeloid leukemia (AML) consisting of daunorubicin and...

Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma

This is a research study to see if a new drug called bortezomib is useful to treat multiple myeloma in people who are newly diagnosed, and have not yet received treatment for their disease...

Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma

Velcade (bortezomib, PS-341) has recently been approved by the Food and Drug Administration (FDA) for the treatment of multiple myeloma (MM) for patients who have received at least one pri...

Companies [58 Associated Companies listed on BioPortfolio]

Millennium Dental Technologies, Inc.

Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a first-in-class proteasome inhibitor, and has a robust cl...

Millennium Pharmaceuticals, Inc.

Millennium Pharmaceuticals, The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical developme...

Millennium: The Takeda Oncology Company

Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets a first-in-class proteasome inhibitor, and has a robust clinical de...

Millennium Pharmacy Systems, Inc.

Millennium Pharmacy Systems is a pharmacy services provider to the long-term care industry. Offering a new approach to pharmacy services, Millennium delivers on the promise of "the right drug, for th...

Millennium Marketing®

The mission of Millennium Marketing® is to provide businesses with information that will help them make more effective decisions.At Millennium Marketing® we will always do what's in the best int...

More Information about "3rd Millennium, Inc" on BioPortfolio

We have published hundreds of 3rd Millennium, Inc news stories on BioPortfolio along with dozens of 3rd Millennium, Inc Clinical Trials and PubMed Articles about 3rd Millennium, Inc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of 3rd Millennium, Inc Companies in our database. You can also find out about relevant 3rd Millennium, Inc Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record